Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Assessment of the adherence to and costs of the prophylaxis protocol for venous thromboembolism

Full text
Author(s):
Forgerini, Marcela [1] ; Varallo, Fabiana Rossi [2] ; Alves de Oliveira, Alice Rosa [1] ; de Nada, Tales Rubens [3] ; Mastroianni, Patricia de Carvalho [1]
Total Authors: 5
Affiliation:
[1] Univ Estadual Sao Paulo, Fac Ciencias Farmaceut, Dept Farmacos & Medicamentos, UNESP, Araraquara, SP - Brazil
[2] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Ciencias Farmaceut, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Cirurgia & Anat, Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Clinics; v. 74, 2019.
Web of Science Citations: 0
Abstract

OBJECTIVES: Evaluate adherence to the therapeutic prophylaxis protocol for venous thromboembolism (VTE) as well as the costs of this practice. METHODS: A descriptive and cross-sectional study was conducted at a State General Hospital in Brazil through reports of drug dispensions, prescriptions and risk stratification of patients. Adherence to the VTE prophylaxis protocol was monitored. The tests for VTE diagnosis measured the adherence to therapeutic prophylaxis treatment, and the purchase prices of the drugs went into the calculation of drug therapy costs. The level of adherence to prescriptions for VTE prophylaxis in the hospital was classified as “adherence”, “non-adherence” and “justified non-adherence” when compared with the protocol. RESULTS: Protocol adherence was observed for 50 (30.9%) patients, and non-adherence was observed for 63 (38.9%) patients, generating an additional cost of $180.40/month. Justified non-adherence in 49 (30.2%) patients generated $514.71/month in savings due to a reduction in the number of daily administrations of unfractionated heparin while still providing an effective method for preventing VTE. Twenty-six patients stratified as having medium to high risk of VTE who did not receive prophylaxis were identified, generating $154.41 in savings. However, these data should be evaluated with caution since the risks and outcomes associated with not preventing VTE outweigh the economy achieved from not prescribing a drug when a patient needs it. The only case of VTE identified during the study period was related to justified non-adherence to the protocol. CONCLUSION: The protocol is based on scientific evidence that describes an effective therapy to prevent VTE. However, the protocol should be updated because the justifications for non-adherence are based on scientific evidence, and this justified non-adherence generates savings and yields effective disease prevention. (AU)

FAPESP's process: 18/07501-9 - Genetic determinants of gastrointestinal bleeding associated with the use of ASA as an antiplalet agent: a case-control study
Grantee:Marcela Forgerini
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 13/12681-2 - Evaluation of the prophylactic use of omeprazole in patients admitted to the State Hospital of Américo Brasiliense
Grantee:Patricia de Carvalho Mastroianni
Support Opportunities: Regular Research Grants